Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives
- PMID: 18004132
- DOI: 10.1097/jcp.0b013e31815ac4e5
Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives
Abstract
Hyperprolactinemia is increasingly studied as a frequent and potentially important consequence of antipsychotic medication treatment. Some individuals presenting with hyperprolactinemia remain asymptomatic, but others may exhibit a wide range of clinical symptoms resulting from either the direct effects of prolactin on body tissues (galactorrhea, gynecomastia) or endocrine-related secondary effects (sexual and reproductive dysfunction in the short term, and possibly the risk of tumorigenesis and osteoporosis in the longer term). Short-term side effects may negatively impact medication compliance, and long-term effects have the potential for serious health consequences. Antipsychotic medications have differing propensities to cause prolactin elevation. The first-generation antipsychotics, as well as the second-generation antipsychotic risperidone and its active metabolite paliperidone, have been shown to cause marked and sustained elevations in prolactin levels, whereas others of the second-generation antipsychotics appear to have little or no effect on prolactin levels or may decrease prolactin. A comprehensive overview of antipsychotics and hyperprolactinemia is presented together with a review of emerging evidence about the short- and long-term health risks of hyperprolactinemia.
Similar articles
-
Antipsychotic-induced hyperprolactinemia.Pharmacotherapy. 2009 Jan;29(1):64-73. doi: 10.1592/phco.29.1.64. Pharmacotherapy. 2009. PMID: 19113797 Review.
-
[Impact of neuroleptic-induced hyperprolactinemia on sexual dysfunction in male schizophrenic patients].Psychiatr Pol. 2008 Jan-Feb;42(1):87-95. Psychiatr Pol. 2008. PMID: 18567406 Review. Polish.
-
Prolactin awareness: an essential consideration for physical health in schizophrenia.Eur Neuropsychopharmacol. 2008 May;18 Suppl 2:S108-14. doi: 10.1016/j.euroneuro.2008.02.004. Eur Neuropsychopharmacol. 2008. PMID: 18346598 Review.
-
Antipsychotic-induced hyperprolactinemia and sexual dysfunction.Psychopharmacol Bull. 2002 Winter;36(1):143-64. Psychopharmacol Bull. 2002. PMID: 12397853 Review.
-
Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences.J Clin Psychiatry. 2002;63 Suppl 4:56-62. J Clin Psychiatry. 2002. PMID: 11913677 Review.
Cited by
-
Physical health monitoring for people with schizophrenia.Aust Prescr. 2023 Dec;46(4):75-79. doi: 10.18773/austprescr.2023.024. Aust Prescr. 2023. PMID: 38152317 Free PMC article. Review.
-
Prolactin Level Changes according to Atypical Antipsychotics Use: A Study Based on Clinical Data Warehouse.Clin Psychopharmacol Neurosci. 2023 Nov 30;21(4):769-777. doi: 10.9758/cpn.23.1057. Epub 2023 Jun 7. Clin Psychopharmacol Neurosci. 2023. PMID: 37859450 Free PMC article.
-
Development of a Guideline for Antipsychotic-induced Hyperprolactinemia in Korea Using the ADAPTE Process.Clin Psychopharmacol Neurosci. 2023 Aug 31;21(3):447-456. doi: 10.9758/cpn.22.979. Clin Psychopharmacol Neurosci. 2023. PMID: 37424413 Free PMC article.
-
Effectiveness and safety of blonanserin in young and middle-aged female patients with schizophrenia: data from a post-marketing surveillance.BMC Psychiatry. 2023 Feb 21;23(1):115. doi: 10.1186/s12888-023-04598-y. BMC Psychiatry. 2023. PMID: 36810039 Free PMC article.
-
Risperidone Induced Hyperprolactinemia: From Basic to Clinical Studies.Front Psychiatry. 2022 May 6;13:874705. doi: 10.3389/fpsyt.2022.874705. eCollection 2022. Front Psychiatry. 2022. PMID: 35599770 Free PMC article. Review.
